Alps Announces Closing of Business Combination with Globalink Investment Inc.

Alps Group Inc., the parent of Alps Life Sciences Inc. (Alps Holdco), and Globalink Investment Inc., a SPAC, jointly announced the successful closing of their business combination. The transaction consisted of a redomestication merger (Globalink merging into Alps Group, which remains the publicly traded entity) followed by an acquisition merger in which a merger subsidiary combined with Alps Holdco, making Alps Holdco a wholly owned subsidiary of Alps Group. Alps ordinary shares began trading on Nasdaq under the ticker "ALPS" on October 31, 2025, while its warrants trade OTC as "ALPWF." The combined company’s estimated enterprise value is approximately US$1.6 billion. Concurrently, the parties completed a PIPE subscription totaling about US$3.1 million to support growth and working capital. Alps, headquartered in Kuala Lumpur, focuses on predictive, preventive and precision medicine, including genomics, mRNA and personalized vaccines, and cellular therapies. The company plans to operate under the name Alps Group Inc. with its headquarters in Malaysia.